DS
ITCI

David Shaw’s Intra-Cellular Therapies Inc. ITCI Stock Holding History

David Shaw’s Portfolio ITCI Stock Details ITCI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-923,809
Closed -$122M – 4836
2025
Q1 		$122M Buy
923,809
+389,348
+73% +$48.5M 0.11% 225
2024
Q4 		$44.6M Buy
534,461
+165,781
+45% +$13.6M 0.03% 615
2024
Q3 		$27M Sell
368,680
-211,679
-36% -$15.9M 0.02% 825
2024
Q2 		$39.7M Buy
580,359
+190,080
+49% +$13.2M 0.04% 536
2024
Q1 		$27M Sell
390,279
-121,271
-24% -$8.33M 0.02% 760
2023
Q4 		$36.6M Sell
511,550
-229,827
-31% -$13.2M 0.03% 601
2023
Q3 		$38.6M Sell
741,377
-211,465
-22% -$12.3M 0.04% 524
2023
Q2 		$60.3M Buy
952,842
+442,938
+87% +$27.6M 0.06% 370
2023
Q1 		$27.6M Sell
509,904
-3,596
-0.7% -$174K 0.03% 704
2022
Q4 		$27.2M Buy
513,500
+163,422
+47% +$8.19M 0.03% 724
2022
Q3 		$16.3M Buy
350,078
+11,417
+3% +$596K 0.02% 987
2022
Q2 		$19.3M Sell
338,661
-25,957
-7% -$1.47M 0.02% 890
2022
Q1 		$22.3M Buy
364,618
+211,031
+137% +$11M 0.02% 958
2021
Q4 		$8.04M Buy
+153,587
New +$6.45M 0.01% 1884
2021
Q3 		– Sell
-48,063
Closed -$1.96M – 5290
2021
Q2 		$1.96M Sell
48,063
-71,936
-60% -$2.66M ﹤0.01% 2959
2021
Q1 		$4.07M Buy
119,999
+22,096
+23% +$767K ﹤0.01% 2011
2020
Q4 		$3.11M Sell
97,903
-131,700
-57% -$3.46M ﹤0.01% 2240
2020
Q3 		$5.89M Buy
229,603
+48,518
+27% +$1.11M 0.01% 1580
2020
Q2 		$4.65M Sell
181,085
-5,362
-3% -$109K 0.01% 1704
2020
Q1 		$2.87M Sell
186,447
-44,966
-19% -$977K ﹤0.01% 1894
2019
Q4 		$7.94M Buy
231,413
+1,887
+0.8% +$22.6K 0.01% 1376
2019
Q3 		$1.71M Sell
229,526
-125,362
-35% -$1.2M ﹤0.01% 2473
2019
Q2 		$4.61M Buy
354,888
+42,630
+14% +$547K 0.01% 1646
2019
Q1 		$3.8M Buy
312,258
+89,687
+40% +$1.15M ﹤0.01% 1728
2018
Q4 		$2.54M Buy
222,571
+27,758
+14% +$448K ﹤0.01% 1960
2018
Q3 		$4.23M Buy
194,813
+11,743
+6% +$246K 0.01% 1690
2018
Q2 		$3.23M Sell
183,070
-39,501
-18% -$802K ﹤0.01% 1855
2018
Q1 		$4.68M Buy
222,571
+184,416
+483% +$3.59M 0.01% 1453
2017
Q4 		$552K Buy
+38,155
New +$589K ﹤0.01% 2932
2017
Q2 		– Sell
-29,192
Closed -$474K – 3577
2017
Q1 		$474K Sell
29,192
-89,198
-75% -$1.29M ﹤0.01% 2758
2016
Q4 		$1.79M Buy
118,390
+81,469
+221% +$1.15M ﹤0.01% 2070
2016
Q3 		$563K Sell
36,921
-31,491
-46% -$1.27M ﹤0.01% 2735
2016
Q2 		$2.66M Buy
+68,412
New +$2.46M ﹤0.01% 1719
2016
Q1 		– Sell
-12,600
Closed -$678K – 3841
2015
Q4 		$678K Sell
12,600
-51,778
-80% -$2.61M ﹤0.01% 2889
2015
Q3 		$2.58M Buy
64,378
+25,678
+66% +$837K ﹤0.01% 1908
2015
Q2 		$1.24M Buy
+38,700
New +$981K ﹤0.01% 2545

Other funds holding ITCI

DekaBank Deutsche Girozentrale
DekaBank Deutsche Girozentrale Frankfurt, Germany $59.2B AUM 26.02% 1-Year Est. Return
Osaic Holdings
Osaic Holdings Scottsdale, Arizona $85.1B AUM 27.35% 1-Year Est. Return
KIM
Kestra Investment Management Austin, Texas $5.16B AUM 18.64% 1-Year Est. Return
HNB
Huntington National Bank Columbus, Ohio $20.6B AUM 34.61% 1-Year Est. Return

David Shaw's ITCI Position: Q2 2025 in Review

David Shaw sold out of Intra-Cellular Therapies Inc. (ITCI) in Q2 2025, closing a stake of 923,809 shares — an estimated $122M sold.

David Shaw first reported a position in ITCI in Q2 2015 and held it in 36 quarters. The position peaked at $122M in Q1 2025. 4 funds tracked by Wall St. Rank hold ITCI as of Q2 2025.

  • David Shaw reported no remaining Intra-Cellular Therapies Inc. position as of Q2 2025 after selling out during the quarter.
  • David Shaw sold 923,809 Intra-Cellular Therapies Inc. shares in Q2 2025, an estimated $122M.
  • David Shaw first reported a position in Intra-Cellular Therapies Inc. in Q2 2015 and held it in 36 quarters.
  • David Shaw's Intra-Cellular Therapies Inc. position peaked at $122M in Q1 2025.
  • 4 funds tracked by Wall St. Rank held Intra-Cellular Therapies Inc. as of Q2 2025.

Based on D.E. Shaw & Co's 13F filing for Q2 2025, filed 14 Aug 2025.